

# Contents

<b>WHO Expert Committee on Drug Dependence</b>	<b>vi</b>
Members	vj
Temporary advisers	vi
Representatives of other organizations	vii
WHO Secretariat (WHO Headquarters, Geneva, Switzerland)	vii
<b>Abbreviations</b>	<b>viii</b>
<b>1. Introduction</b>	<b>1</b>
<b>Declarations of interest</b>	<b>3</b>
<b>2. WHO Expert Committee on Drug Dependence (ECDD): review procedures and processes</b>	<b>5</b>
2.1 Pre-reviews and critical reviews	5
2.2 Member State questionnaires	5
<b>3. Open session</b>	<b>6</b>
<b>4. Briefings from international organizations on their work on the public health dimension of the world drug problem</b>	<b>8</b>
4.1 Update from the international Narcotics Control Board	8
4.2 Update from the United Nations Office on Drugs and Crime	9
4.3 Update from the World Health Organization	10
<b>5. Review of substances</b>	<b>12</b>
<b>6. Cannabidiol</b>	<b>13</b>
6.1 Substance identification	13
6.2 Chemistry	13
6.3 Ease of convertibility into controlled substances	13
6.4 General pharmacology	13
6.5 Toxicology	14
6.6 Adverse reactions in humans	14
6.7 Dependence potential	14
6.8 Abuse potential	14
6.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	15
6.10 Listing in the WHO Model List of Essential Medicines	15
6.11 Marketing authorizations (as a medicinal product)	16
6.12 Industrial use	16
6.13 Non-medical use, abuse and dependence	16
6.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	16
6.15 Licit production, consumption and international trade	16
6.16 Illicit manufacture and traffic and related information	16
6.17 Current international controls and their impact	16
6.18 Current and past national controls	17
6.19 WHO review history	17
6.20 Recommendation	17

•

<b>7. Cannabis and cannabis resin</b>	<b>18</b>
7.1 Substance identification	18
7.2 Chemistry	18
7.3 Ease of convertibility into controlled substances	19
7.4 General pharmacology	19
7.5 Toxicology	20
7.6 Adverse reactions in humans	20
7.7 Dependence potential	21
7.8 Abuse potential	21
7.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	22
7.10 Listing on the WHO Model List of Essential Medicines	22
7.11 Marketing authorizations (as a medicinal product)	22
7.12 Industrial use	22
7.13 Non-medical use, abuse and dependence	22
7.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	23
7.15 Licit production, consumption and international trade	23
7.16 Illicit manufacture and traffic and related information	23
7.17 Current international controls and their impact	23
7.18 Current and past national controls	23
7.19 WHO review history	23
7.20 Recommendation	24
<b>8. Extracts and tinctures of cannabis</b>	<b>25</b>
8.1 Substance identification	25
8.2 Chemistry	25
8.3 Ease of convertibility into controlled substances	27
8.4 General pharmacology	27
8.5 Toxicology	28
8.6 Adverse reactions in humans	28
8.7 Dependence potential	29
8.8 Abuse potential	29
8.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	29
8.10 Listing on the WHO Model List of Essential Medicines	30
8.11 Marketing authorizations (as a medicinal product)	30
8.12 Industrial use	30
8.13 Non-medical use, abuse and dependence	30
8.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	30
8.15 Licit production, consumption and international trade	30
8.16 Illicit manufacture and traffic and related information	31
8.17 Current international controls and their impact	31
8.18 Current and past national controls	31
8.19 WHO review history	31
8.20 Recommendation	31
<b>9. Delta-9-tetrahydrocannabinol ( d r o n a b i n o l )</b>	<b>33</b>
9.1 Substance identification	33

9.2 Chemistry	33
9.3 Ease of convertibility into controlled substances	33
9.4 General pharmacology	34
9.5 Toxicology	35
9.6 Adverse reactions in humans	35
9.7 Dependence potential	36
9.8 Abuse potential	36
9.9 Therapeutic applications and extent of therapeutic use and epidemiology of medical use	37
9.10 Listing on the WHO Model List of Essential Medicines	37
9.11 Marketing authorizations (as a medicinal product)	37
9.12 Industrial use	37
9.13 Non-medical use, abuse and dependence	38
9.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	38
9.15 Licit production, consumption and international trade	38
9.16 Illicit manufacture and traffic and related information	38
9.17 Current international controls and their impact	38
9.18 Current and past national controls	38
9.19 WHO review history	38
9.20 Recommendation	40

<b>10. Tetrahydrocannabinol (Isomers of THC)</b>	<b>42</b>
10.1 Substance identification	42
10.2 Chemistry	42
10.3 Ease of convertibility into controlled substances	42
10.4 General pharmacology	42
10.5 Toxicology	43
10.7 Dependence potential	43
10.8 Abuse potential	43
10.9 Therapeutic applications, extent of therapeutic use and epidemiology of medical use	44
10.10 Listing in the WHO Model List of Essential Medicines	44
10.11 Marketing authorizations (as a medicinal product)	44
10.12 Industrial use	44
10.13 Non-medical use, abuse and dependence	44
10.14 Nature and magnitude of public health problems related to misuse, abuse and dependence	44
10.15 Licit production, consumption and international trade	45
10.16 Illicit manufacture and traffic and related information	45
10.17 Current international controls and their impact	45
10.18 Current and past national controls	45
10.19 WHO review history	45
10.20 Recommendation	45
<b>11. Summary</b>	<b>46</b>
<b>Acknowledgements</b>	<b>47</b>
<b>References</b>	<b>48</b>